Summit Therapeutics PLC ADR (SMMT)

Currency in USD
9.950
-0.620(-5.87%)
Closed·
10.020+0.070(+0.70%)
·
Trading near 52-week Low
SMMT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.89010.610
52 wk Range
9.89029.230
Key Statistics
Prev. Close
10.57
Open
10.28
Day's Range
9.89-10.61
52 wk Range
9.89-29.23
Volume
7.02M
Average Volume (3m)
6.69M
1-Year Change
-39.5137%
Book Value / Share
0.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SMMT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.824
Upside
+189.69%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

11 Buy
5 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 28.824
(+189.69% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink
Hold---MaintainNov 18, 2026
Bernstein SocGen Group
Sell8.30-16.58%-DowngradeNov 18, 2026
Barclays
Hold18.00+80.90%20.00MaintainNov 16, 2026
Jefferies
Buy30.00+201.51%-MaintainNov 15, 2026
Stifel
Buy37.00+271.86%38.00MaintainNov 05, 2026

Summit Therapeutics PLC ADR Earnings Call Summary for Q2/2026

  • Summit posted Q2 loss of $0.37/share vs. $0.28 expected, a 32.6% miss; shares fell 4.6% after hours despite 1.6% regular-session gain.
  • Cash rose to $690.7M from $598.7M in Q1 via $231M ATM raise; operating expenses jumped 24% to $151.8M on three Phase III trials.
  • Updated HARMONi survival data showed 0.76 hazard ratio; company maintains Nov. 14, 2026 PDUFA date for ivonescimab in EGFR-mutated NSCLC.
  • Key milestones: HARMONi-3 squamous PFS data H2 2026, OS interim analysis H1 2027, Arcus collaboration data mid-2027.
  • Filed new $380M ATM facility for financing flexibility; commercial launch prep underway with leadership in place, field force hiring near approval.
Last Updated: 07/24/2026, 05:50 AM
Read Full Transcript

Earnings

Latest Release
Nov 04, 2026
EPS / Forecast
-0.27 / -0.29
Revenue / Forecast
-- / 71.43K
EPS Revisions
Last 90 days

SMMT Income Statement

Compare SMMT to Peers and Sector

Metrics to compare
SMMT
Peers
Sector
Relationship
P/E Ratio
−10.2x−2.6x−0.2x
PEG Ratio
−0.69−0.030.00
Price/Book
15.0x1.9x2.6x
Price / LTM Sales
-182.2x2.7x
Upside (Analyst Target)
172.7%172.6%72.2%
Fair Value Upside
Unlock3.4%12.4%Unlock

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
48.13M6.02%505.36M
Other Institutional Investors
118.42M14.81%1.24B
Public Companies & Retail Investors
633.22M79.18%6.65B
Total
799.76M100.00%8.4B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Baker Bros. Advisors LP4.10%32,786,348344,257
Akeso, Inc.4.01%32,057,147336,600

People Also Watch

88.91
ANT
-8.50%
39.51
CRWV
-12.02%
82.67
CBRS
-4.93%
460.54
LITE
-13.94%
32.930
AAOI
-16.55%

FAQ

What Is the Summit Therapeutics PLC ADR (SMMT) Stock Price Today?

The Summit Therapeutics PLC ADR stock price today is 9.950 USD.

What Stock Exchange Does Summit Therapeutics PLC ADR Trade On?

Summit Therapeutics PLC ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Summit Therapeutics PLC ADR?

The stock symbol for Summit Therapeutics PLC ADR is "SMMT."

What Is the Summit Therapeutics PLC ADR Market Cap?

As of today, Summit Therapeutics PLC ADR market cap is 8.450B USD.

What Is Summit Therapeutics PLC ADR's Earnings Per Share (TTM)?

The Summit Therapeutics PLC ADR EPS (TTM) is -1.07.

When Is the Next Summit Therapeutics PLC ADR Earnings Date?

Summit Therapeutics PLC ADR will release its next earnings report on Mar 18, 2027.

From a Technical Analysis Perspective, Is SMMT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Summit Therapeutics PLC ADR Stock Split?

Summit Therapeutics PLC ADR has split 0 times.

How Many Employees Does Summit Therapeutics PLC ADR Have?

Summit Therapeutics PLC ADR has 265 employees.

What is the current trading status of Summit Therapeutics PLC ADR (SMMT)?

As of Nov 21, 2026, Summit Therapeutics PLC ADR (SMMT) is trading at a price of 9.950 USD, with a previous close of 10.570 USD. The stock has fluctuated within a day range of 9.890 USD to 10.610 USD, while its 52-week range spans from 9.890 USD to 29.230 USD.

What Is Summit Therapeutics PLC ADR (SMMT) Price Target According to Analysts?

The average 12-month price target for Summit Therapeutics PLC ADR is 28.824 USD, with a high estimate of 42.61992136 USD and a low estimate of 8.2293578 USD. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +189.69% Upside potential.

What Is the SMMT Premarket Price?

SMMT's last pre-market stock price is 10.340 USD. The pre-market share volume is 55,990.000, and the stock has decreased by -0.230, or -2.180%.

What Is the SMMT After Hours Price?

SMMT's last after hours stock price is 10.020 USD, the stock has decreased by 0.070, or 0.700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.